Speedy FDA approval puts Stehlin anticancer drug in clinical trials
A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials.
Generally, only five potential anticancer drugs out of every 5,000 to 10,000 developed are approved by the FDA for Phase 1 trials.
The drug, CZ48, is derived from a Chinese tree, Camptotheca, whose anticancer potential was discovered in the 1960s.